Germany · Delayed Price · Currency is EUR Actinium Pharmaceuticals Statistics
Total Valuation
FRA:7AY1 has a market cap or net worth of EUR 36.76 million. The enterprise value is -8.18 million.
| Market Cap | 36.76M |
| Enterprise Value | -8.18M |
Important Dates
The last earnings date was Friday, November 21, 2025.
| Earnings Date | Nov 21, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 31.20M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +7.11% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 1.08% |
| Owned by Institutions (%) | 19.88% |
| Float | 30.86M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 11.06 |
| PS Ratio | 479.27 |
| PB Ratio | 3.13 |
| P/TBV Ratio | 3.13 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.28 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.96, with a Debt / Equity ratio of 0.08.
| Current Ratio | 7.96 |
| Quick Ratio | 7.81 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -133.09% and return on invested capital (ROIC) is -85.10%.
| Return on Equity (ROE) | -133.09% |
| Return on Assets (ROA) | -33.76% |
| Return on Invested Capital (ROIC) | -85.10% |
| Return on Capital Employed (ROCE) | -75.71% |
| Revenue Per Employee | 3,068 |
| Profits Per Employee | -1.18M |
| Employee Count | 37 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -7.09% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -7.09% |
| 50-Day Moving Average | 1.24 |
| 200-Day Moving Average | 1.29 |
| Relative Strength Index (RSI) | 54.17 |
| Average Volume (20 Days) | 81 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.12 |
Income Statement
In the last 12 months, FRA:7AY1 had revenue of EUR 76,707 and -29.49 million in losses. Loss per share was -0.95.
| Revenue | 76,707 |
| Gross Profit | 76,707 |
| Operating Income | -31.82M |
| Pretax Income | -29.49M |
| Net Income | -29.49M |
| EBITDA | -31.64M |
| EBIT | -31.82M |
| Loss Per Share | -0.95 |
Balance Sheet
The company has 45.51 million in cash and 974,179 in debt, giving a net cash position of 44.53 million.
| Cash & Cash Equivalents | 45.51M |
| Total Debt | 974,179 |
| Net Cash | 44.53M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 11.75M |
| Book Value Per Share | 0.38 |
| Working Capital | 40.51M |
Cash Flow
| Operating Cash Flow | -21.34M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -41,486.67% |
| Pretax Margin | -38,443.33% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:7AY1 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.11% |
| Shareholder Yield | -7.11% |
| Earnings Yield | -80.21% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 11, 2020. It was a reverse split with a ratio of 0.0333333333.
| Last Split Date | Aug 11, 2020 |
| Split Type | Reverse |
| Split Ratio | 0.0333333333 |
Scores
FRA:7AY1 has an Altman Z-Score of -10.59 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.59 |
| Piotroski F-Score | 2 |